ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.
One vaccine, three routes for activating the entire immune system and providing T cell, B cell memory, and mucosal protection The first COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous, sublingual, and oral Oral capsule stimulates immunity to both S and N proteins and could potentially serve as a universal boost to other S-based (antibody-based) vaccines and reduce transmission T-cell vaccine could potentially address escape mutant variants to S proteins CULVER CITY & EL SEGUNDO, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc.,...
Source: naija247news.com
